Adamas Pharmaceuticals Inc
DelistedCIK 1328143fmd_0156PNZJ49QJ4EVB7VAJZK93SWManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2021, 36 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 37 | 71 | 56 | 2 | 1 | 1 | 34 | 55 | 74 |
| Cost of revenue | – | – | – | 0 | 0 | 0 | 1 | 2 | 2 |
| Gross profit | – | – | – | 2 | 1 | 1 | 33 | 52 | 72 |
| Research and development | 9 | 7 | 22 | 36 | 31 | 27 | 39 | 30 | 10 |
| Selling, general and administrative | – | – | – | 23 | 30 | 61 | 109 | 114 | 107 |
| Total operating expenses | 18 | 14 | 37 | 59 | 62 | 88 | – | – | – |
| Operating income | 20 | 57 | 19 | (57) | (61) | (88) | (115) | (92) | (44) |
| Interest expense | – | – | – | 0 | 0 | 5 | 19 | 15 | 14 |
| Income before taxes | 18 | 52 | 18 | (57) | (60) | (91) | (131) | (105) | (57) |
| Income tax expense | 0 | 1 | 7 | (5) | (0) | (2) | 0 | 0 | 0 |
| Net income from continuing operations | 18 | 51 | 10 | (52) | (60) | (89) | (131) | (105) | (57) |
| Net income | 18 | 51 | 10 | (52) | (60) | (89) | (131) | (105) | (57) |
| Net income to common shareholders | 11 | 33 | 9 | (52) | (60) | – | – | – | – |